2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3770 Implications of initial mutation profiles of myelofibrosis patients – baseline molecular data of the longitudinal myeloproliferative neoplasms research consortium tissue bank

Brian Chernak, MD, Duke J. Butterfield, MA2, Blake Langlais, MS3, Bridget Kelly Marcellino, MD, PhD4, Noushin Farnoud, PhD, MASc5, Fawzaan Hashmi, BS6, Erin McGovern, BA7, Raajit K. Rampal, MD, PhD8, John O. Mascarenhas, MD9, Amylou C Dueck, PhD10, Ronald Hoffman, MD11
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States
2 Mayo Clinic, Phoenix, Arizona, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States
3 Mayo Clinic, Scottsdale, Arizona, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States
10 Mayo Clinic, Scottsdale, Arizona, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States, Myeloproliferative Neoplasms Research Consortium, New York, New York, United States

Myelofibrosis (MF) is driven by mutations in the JAK-STAT signaling pathway and associated with generalized symptoms, splenomegaly and a risk of transformation to acute myeloid leukemia. Although the role of driver mutations (JAK2, CALR, MPL) are well recognized in the pathophysiology of MF, the differential effects of co-occurring somatic mutations on disease manifestations, such as patient symptoms and the degree of splenomegaly, remain largely unknown.

Methods: We report the baseline characteristics of MF patients collected within the Myeloproliferative Neoplasms Research Consortium (MPN-RC) Tissue Bank, a large longitudinal database encompassing clinical parameters, genomic analysis, and patient-reported outcomes. Group comparisons used equal-variance two-sample t tests or chi-square tests. Pearson correlations (r) were calculated using available cases. Analyses were exploratory; p-values were nominal and were not adjusted for multiple testing.

Results: 278 MF patient samples were collected at study enrollment and were analyzed; 172 (61.9%) from patients with primary MF(PMF), 40 (14.4%) with post-essential thrombocythemia MF(ET-MF), 35 (12.6%) with post-polycythemia vera MF(PV-MF), and 31 (11.2%) with pre-fibrotic PMF. There were no differences in age, sex, race, or ethnicity among the disease subcategories. Patients with pre-fibrotic PMF had a lower symptom burden by MPN-SAF TSS compared to overt MF (ET-MF, PV-MF, PMF) (mean 12.0 vs. 19.6, p=0.041). Average spleen size was significantly different among subgroups (p=0.012), with PV-MF the largest (10.9cm).

Of the 278 patients, NGS was available for 254 patients. Mutually exclusive driver assignment (based on the higher VAF if multiple present) yielded JAK2 (n=133; 52.4%); CALR (n=59; 23.2%), MPL (n=22; 8.7%), or triple-negative (TN: absent JAK2/CALR/MPL) MF (n=40; 15.7%).  Mean age between driver mutations were significantly different, and youngest in CALRmut (mean: 59.2y vs. 66.4y (non-CALRmut), p<0.001). Overall symptom burden by MPN-SAF TSS and MF-SAF TSS were not different by driver mutations. CALRmut MF was associated with higher platelet counts (371 vs. 265 x 109/L, p=0.003).

JAK2mut and MPLmut MF were enriched for TET2 mutations (33.1% vs. 17.8%, p=0.006; 44.0% vs. 24.0%, p=0.031); conversely, TN MF was associated with fewer TET2 mutations (p=0.004) but did not exhibit a difference in spleen size or symptom burden.

The presence of high molecular risk mutations (HMR: ASXL1, EZH2, SRSF2, IDH1, IDH2, U2AF1 or TP53) were detected in 104 of 254 patients (40.9%) and found in older patients (mean 69.4y vs. no HMRmut 64.3y, p=0.001); HMRmut were associated with larger non-zero mean palpable spleens (12.0cm vs. 9.0cm, p=0.009). There were significant differences in HMRmut by driver mutational status (p=0.049) and numerically enriched in JAK2mut MF (46.3% vs. non-JAK2mut: 34.7%, p=0.061). Mean white blood cell (WBC) count was greater (14.2 vs. 9.8 x 109/L, p=0.003) and platelet counts were lower (248 vs. 318 x 109/L, p=0.024) in HMRmut MF. SRSF2 mutations were near-exclusive to JAK2/MPLmut MF, with only 1 CALRmut patient harboring a co-occurring SRSF2mut (1.6% vs. 16.1% non-CALRmut MF, p=0.003), however this patient’s disease was likely MPLmut-driven due to greater VAF. Similarly, only 1 TN MF patient had a SRSF2mut (2.5% vs. 14.5% non-TN MF, p=0.036). TET2 prevalence was also associated with SRSF2 co-mutation (22.7% vs. 9.0%, p=0.004).

In available-case exploratory analysis, JAK2 VAF was correlated with U2AF1 VAF (r=0.76, p=0.003), SRSF2 VAF (r=0.57, p=0.004), and TET2 VAF (r =0.38, p=0.010). A weak correlation was found between JAK2 VAF and spleen size (r=0.28, p=0.040). CALR VAF was correlated with reduced overall quality of life (r=0.31, p=0.024). SRSF2 VAF correlated with increased MPN-SAF TSS (r=0.43, p=0.030), and worsening early satiety (r=0.52, p=0.005). Both SRSF2 and TET2 VAF correlated with unintentional weight loss (SRSF2: r=0.40, p=0.041; TET2: r=0.370, p=0.01) and inactivity (SRSF2: r=0.28, p=0.048; TET2: r=0.36, p=0.014).

Conclusion: Disease phenotype in MF is associated with differences in gene mutational status, involving not only driver mutations but also secondary co-mutations. SRSF2 mutations were near-exclusive to JAK2/MPL-driven MF, and SRSF2 and TET2 VAF correlated with several symptoms. Clustering of secondary mutations likely influence disease phenotype, symptoms, and clinical splenomegaly in MF more than previously reported.

Brian Chernak, MD: Cogent Biosciences - Honoraria; Refined Oncology - Honoraria; Integritas Communications - Honoraria; Plexus Communications - Honoraria; Sobi - Consultancy (Includes expert testimony); Geron Corporation - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony)